Life sciences and healthcare companies that set out to pioneer treatments in rare and specialty disease face a unique set of challenges. Typical pitfalls for advancing an indication in this space...

Nitin Choudhary, Managing Principal of IPM.ai and Richard Wilson, Rare Disease Franchise Head for Kyowa Kirin recently spoke on overcoming patient-finding challenges through machine learning (ML)...

Conventional clinical study recruitment methods for rare diseases simply don’t work. Analyzing ICD-10 and prescription data to determine patient clusters, site selection and feasibility is...

August 19, 2021

Real Chemistry's IPM.ai Expands Partnership with Datavant

0

San Francisco – Aug. 19, 2021 – Real Chemistry’s IPM.ai, the leader in uncovering undiagnosed and misdiagnosed patients via machine learning, and Datavant, the leader in helping healthcare and...

July 29, 2021

IPM.ai Accelerates the Clinical Study and Commercialization of Precision...

0

Targeted Approach Optimizes Clinical Study Recruitment of Medically-Eligible Patients Affected by Rare Diseases